DelMar Pharmaceuticals – Breakthrough Cancer Therapeutics

DelMar Pharmaceuticals (OTCQX:DMPI) is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. The company’s lead product candidate, VAL-083, is a first-in-class small molecule chemotherapy with the potential to overcome chemo-resistance in cancer patients and surpass the current standard of care in a range of cancers.
VAL-083 was originally developed by the US National Cancer Institute (NCI), whose research team evaluated the drug as a treatment against several types of cancer. The NCI conducted 42 Phase I and Phase II clinical trials on the use of VAL-083 to treat lung, brain, cervical, ovarian and hematologic cancers.
The global market for cancer drugs hit $100 billion in annual sales in 2014, according to a research report by drug data provider IMS Health. The report projects that total could reach $147 billion by 2018. Rising cancer rates brought on by an aging population is the biggest growth driver in this market. The number of individuals over the age of 65 is expect to triple by 2050 to 1.5 billion, translating to a 70 percent increase in the rate of cancer, according to the World Health Organization.
Research Highlights

• Completed Phase I dose-escalation in the clinical trial. Data support a dose-dependent response and clinically meaningful survival benefit.
• Completed enrollment for Phase II expansion cohort and confirmed maximum tolerated dose of 40mg/m2.
• Presented data on the activity of VAL-083 against temozolomide-resistant GBM.

Upcoming Catalysts 2016

• Initiation of Phase II/III registration trial of VAL-083 as a new treatment option for refractory GBM.
• Initiation of Phase II clnical trials with VAL-083 in newly diagnosed GBM
• Initiation of Phase IV NSCLC trial funded by DelMar collaboration with Chinese manufacturer.
• Advancing VAL-083 into clinical studies as a potential treatment for children suffering from recurrent medulloblastoma or high grade gliomas.
• Advancing VAL-083 into clinical studies as a potential treatment for ovarian cancers.
• Continued non-clinical research with VAL-083 as a potential treatment option for chemo-resistant cancers.

View the full DelMar Pharmaceuticals (OTCQX:DMPI) educational profile and connect to receive an Investor Presentation.